Sarcopenia in Patients With Parkinson's Disease: A Systematic Review and Meta-Analysis

Cai, Yingying; Feng, Feiling; Wei, Qianqian; Jiang, Zheng; Ou, Ruwei; Shang, Huifang

doi:10.3389/fneur.2021.598035

Cited by 35 publications

(31 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sarcopenia, the progressive loss of muscle mass and function [ 64 , 65 ], is prevalent in older adults living with PD and is associated with the severity of the disease [ 66 , 67 ]. In C. elegans , sarcopenia corresponds to a reduction in mobility, which is assessed by counting the number of body bends, or thrashes, in liquid media.…”

Section: Resultsmentioning

confidence: 99%

Using a Caenorhabditis elegans Parkinson’s Disease Model to Assess Disease Progression and Therapy Efficiency

et al. 2022

View full text Add to dashboard Cite

Despite Parkinson’s Disease (PD) being the second most common neurodegenerative disease, treatment options are limited. Consequently, there is an urgent need to identify and screen new therapeutic compounds that slow or reverse the pathology of PD. Unfortunately, few new therapeutics are being produced, partly due to the low throughput and/or poor predictability of the currently used model organisms and in vivo screening methods. Our objective was to develop a simple and affordable platform for drug screening utilizing the nematode Caenorhabditis elegans. The effect of Levodopa, the “Gold standard” of PD treatment, was explored in nematodes expressing the disease-causing α-synuclein protein. We focused on two key hallmarks of PD: plaque formation and mobility. Exposure to Levodopa ameliorated the mobility defect in C. elegans, similar to people living with PD who take the drug. Further, long-term Levodopa exposure was not detrimental to lifespan. This C. elegans-based method was used to screen a selection of small-molecule drugs for an impact on α-synuclein aggregation and mobility, identifying several promising compounds worthy of further investigation, most notably Ambroxol. The simple methodology means it can be adopted in many labs to pre-screen candidate compounds for a positive impact on disease progression.

show abstract

Section: Resultsmentioning

confidence: 99%

Using a Caenorhabditis elegans Parkinson’s Disease Model to Assess Disease Progression and Therapy Efficiency

et al. 2022

View full text Add to dashboard Cite

show abstract

“…low muscle mass and function) may differ according to the diagnostic criteria used, recent pooled analyses revealed that these conditions are highly prevalent among community‐dwelling 3 and hospitalized older adults 4 as well as patients with lung diseases, 5 liver cirrhosis, 6 cancer, 7 and other diseases. 8 , 9 , 10 Patients may also lose muscle in the presence of obesity (i.e. sarcopenic obesity) or without changes in body weight.…”

Section: Introductionmentioning

confidence: 99%

Mapping ongoing nutrition intervention trials in muscle, sarcopenia, and cachexia: a scoping review of future research

Orsso

Montes‐Ibarra

Findlay

et al. 2022

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Muscle loss alone, or in the context of sarcopenia or cachexia, is a prevalent condition and a predictor of negative outcomes in aging and disease. As adequate nutrition is essential for muscle maintenance, a growing number of studies has been conducted to explore the role of specific nutrients on muscle mass or function. Nonetheless, more research is needed to guide evidence-based recommendations. This scoping review aimed to compile and document ongoing clinical trials investigating nutrition interventions as a strategy to prevent or treat low muscle mass or function (strength and physical performance), sarcopenia, or cachexia. ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform were searched up to 21 April 2021 for planned and ongoing trials. Randomized controlled trials with ≥20 participants per arm were included based on intent to explore the effects of nutrition interventions on muscle-related outcomes (i.e. muscle mass or strength, physical performance, or muscle synthesis rate) in both clinical and non-clinical conditions (i.e. aging). Two reviewers independently screened records for eligibility, and a descriptive synthesis of trials characteristics was conducted. A total of 113 trials were included in the review. Most trials (69.0%) enroll adults with clinical conditions, such as cancer (19.5%), obesity and metabolic diseases (16.8%), and musculoskeletal diseases (10.7%). The effects of nutrition interventions on age-related muscle loss are explored in 31% of trials. Although nutrition interventions of varied types were identified, food supplements alone (48.7%) or combined with dietary advice (11.5%) are most frequently reported. Protein (17.7%), amino acids (10.6%), and β-hydroxy-β-methylbutyrate (HMB, 6.2%) are the top three food supplements' nutrients under investigation. Primary outcome of most trials (54.9%) consists of measures of muscle mass alone or in combination with muscle strength and/or performance (as either primary or secondary outcomes). Muscle strength and physical performance are primary outcomes of 38% and 31.9% of the trials, respectively. These measurements were obtained using a variety of techniques. Only a few trials evaluate muscle synthesis rate either as a primary or secondary outcome (5.3%). Several nutrition studies focusing on muscle, sarcopenia, and cachexia are underway and can inform future research in this area. Although many trials have similar type of interventions, methodological heterogeneity may challenge study comparisons, and future meta-analyses aiming to provide evidence-based recommendations. Upcoming research in this area may benefit from guidelines for the assessment of therapeutic effects of nutrition interventions.

show abstract

“…Parkinson's disease (PD) is the second most common neurodegenerative disease in the elderly [1][2][3][4]. It occurs due to a substantial decrease in dopamine secretion caused by the degeneration of dopaminergic neurons in the substantia nigra pars compacta [5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

“…It occurs due to a substantial decrease in dopamine secretion caused by the degeneration of dopaminergic neurons in the substantia nigra pars compacta [5][6][7][8][9]. Skeletal muscle atrophy has been reported in PD [1][2][3][4]. Overexpression of myostatin, a negative regulator of skeletal muscle mass, has been shown in atrophied skeletal muscles [10].…”

Section: Introductionmentioning

confidence: 99%

Endurance exercise training suppresses myostatin upregulation and nuclear factor-kappa B activation in a mouse model of Parkinson's disease

Erekat

Al-Jarrah²

2022

Vet World

View full text Add to dashboard Cite

Background and Aim: Muscle atrophy is common in Parkinson's disease (PD). Although myostatin has been implicated in muscle atrophy, its expression in PD skeletal muscle has not been investigated. Therefore, this study aimed to elucidate the influence of PD induction and exercise training on myostatin expression in the gastrocnemius skeletal muscle. Materials and Methods: Thirty albino mice were randomly selected and separated into three groups of 10 mice each: Sedentary control, sedentary PD (SPD), and exercised PD (EPD). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine and probenecid were used to induce chronic parkinsonism in the PD groups. Immunohistochemistry was used to investigate the expression of myostatin and nuclear factor kappa B (NF-κB) in gastrocnemius muscles of all three groups. Results: Myostatin expression and NF-κB nuclear localization, indicative of its activation, were significantly (p<0.01) higher in gastrocnemius skeletal muscle in the SPD group than in the control and EPD groups. Concomitantly, the average cross-sectional area of gastrocnemius muscle fibers in the SPD albino mice was significantly smaller (p<0.01) than in the control and EPD groups, indicating muscle atrophy. Conclusion: The present data are the first to indicate a correlation between PD induction and myostatin overexpression and NF-κB activation in the gastrocnemius muscle, potentially promoting the muscle atrophy commonly seen in PD.

show abstract

Sarcopenia in Patients With Parkinson's Disease: A Systematic Review and Meta-Analysis

Cited by 35 publications

References 39 publications

Using a Caenorhabditis elegans Parkinson’s Disease Model to Assess Disease Progression and Therapy Efficiency

Using a Caenorhabditis elegans Parkinson’s Disease Model to Assess Disease Progression and Therapy Efficiency

Mapping ongoing nutrition intervention trials in muscle, sarcopenia, and cachexia: a scoping review of future research

Endurance exercise training suppresses myostatin upregulation and nuclear factor-kappa B activation in a mouse model of Parkinson's disease

Contact Info

Product

Resources

About